Breast Cancer Trial, Recruiting NCT06636370 Sponsor: C.H. van Gils Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06636370
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who take part in the Dutch national breast cancer screening program and received a normal mammogram result (classified as BI-RADS 1 or 2, meaning no concerning findings were detected).
  • People whose breast tissue has been measured as extremely dense (category D) using a specific software tool called Quantra.
  • People aged between 49 and 72 years old.
  • People who live within 60 kilometres of one of the 15 hospitals taking part in the trial.
  • People who do not have breast implants.
  • People who are willing to allow their data to be shared as part of the trial.
  • People who have not previously taken part in either the DENSE trial or the STREAM trial.

Who may not be able to join:

  • People who have certain types of metal inside their body (this applies only to the MRI part of the trial and is checked by phone).
  • People who have previously had an allergic reaction to the contrast dye used in the imaging procedures.
  • People with poorly functioning kidneys, specifically a filtration rate below 30 ml/min (this applies only to one type of imaging called CEM, and is checked using a questionnaire and possibly a kidney function test).
  • People who experience severe claustrophobia (this applies only to the MRI part of the trial).
  • People who weigh more than 150 kilograms (this applies only to the MRI part of the trial).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carla van Gils, Prof., UMC Utrecht

Phone: 0031-88-7568181

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
C.H. van Gils
Registry
ClinicalTrials.gov
Start date
11 November 2024
Est. completion
31 December 2029

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Interval Cancer Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov